Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | RHOC | P08134 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15432467 | 0.82 | TAAR1 (0.57) | IDO1KMT2ATP53BP1DAOCTSL | |
| Ammonia Solution, Strong SCHEMBL28048257 | 0.81 | TAAR1 (0.56) | IDO1KMT2ATP53BP1DAOCTSL | |
| SCHEMBL24999176 | 0.81 | TAAR1 (0.52) | IDO1KMT2ADAOKCNH2 | |
| SCHEMBL15432486 | 0.80 | IDO1 (0.48) | IDO1TACR1ADRB2RHOCRHOA | |
| SCHEMBL2895602 | 0.80 | KMT2A (0.47) | IDO1TACR1KMT2APAX8DAO | |
| Hydrochloric Acid SCHEMBL6545522 | 0.78 | KMT2A (0.46) | IDO1TACR1KMT2APAX8DAO | |
| SCHEMBL2600179 | 0.73 | IDO1 (0.48) | IDO1TACR1KMT2APAX8DAO | |
| SCHEMBL29664562 | 0.72 | CYP3A4 (0.47) | KMT2AADRB2 | |
| SCHEMBL14176505 | 0.72 | NPC1 (0.44) | IDO1KMT2A | |
| SCHEMBL19300959 | 0.72 | SIGMAR1 (0.46) | IDO1TACR1KMT2APAX8DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | IDO1 3745/4885TACR1 3951/4885KMT2A 3123/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | IDO1 3386/4885TACR1 4234/4885KMT2A 3294/4885 |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | IDO1 3745/4885TACR1 3951/4885KMT2A 3123/4885 |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, SMARCE1, MDM2 | IDO1 4494/4885TACR1 4631/4885KMT2A 1673/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | IDO1 3745/4885TACR1 3951/4885KMT2A 3123/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | IDO1 3745/4885TACR1 3951/4885KMT2A 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.